These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 25871992)
1. Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer. Karzai FH; Madan RA; Figg WD South Med J; 2015 Apr; 108(4):224-8. PubMed ID: 25871992 [TBL] [Abstract][Full Text] [Related]
2. Commentary on "Beyond PSA: managing modern therapeutic options in metastatic castration-resistant prostate cancer". Chueh SC South Med J; 2015 Apr; 108(4):229. PubMed ID: 25871993 [No Abstract] [Full Text] [Related]
3. Dynamic changes of alkaline phosphatase are strongly associated with PSA-decline and predict best clinical benefit earlier than PSA-changes under therapy with abiraterone acetate in bone metastatic castration resistant prostate cancer. Mikah P; Krabbe LM; Eminaga O; Herrmann E; Papavassilis P; Hinkelammert R; Semjonow A; Schrader AJ; Boegemann M BMC Cancer; 2016 Mar; 16():214. PubMed ID: 26975660 [TBL] [Abstract][Full Text] [Related]
4. Exponential rise in prostate-specific antigen (PSA) during anti-androgen withdrawal predicts PSA flare after docetaxel chemotherapy in patients with castration-resistant prostate cancer. Han KS; Hong SJ Yonsei Med J; 2015 Mar; 56(2):368-74. PubMed ID: 25683983 [TBL] [Abstract][Full Text] [Related]
5. A multicenter retrospective analysis of sequential treatment of abiraterone acetate followed by docetaxel in Japanese patients with metastatic castration-resistant prostate cancer. Ueda Y; Matsubara N; Takizawa I; Nishiyama T; Tabata K; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H Jpn J Clin Oncol; 2015 Aug; 45(8):774-9. PubMed ID: 25981621 [TBL] [Abstract][Full Text] [Related]
6. Correlation between Prostate-Specific Antigen Kinetics and Overall Survival in Abiraterone Acetate-Treated Castration-Resistant Prostate Cancer Patients. Xu XS; Ryan CJ; Stuyckens K; Smith MR; Saad F; Griffin TW; Park YC; Yu MK; Vermeulen A; Poggesi I; Nandy P Clin Cancer Res; 2015 Jul; 21(14):3170-7. PubMed ID: 25829400 [TBL] [Abstract][Full Text] [Related]
7. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer. Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595 [TBL] [Abstract][Full Text] [Related]
8. Co-introduction of a steroid with docetaxel chemotherapy for metastatic castration-resistant prostate cancer affects PSA flare. Shiota M; Yokomizo A; Takeuchi A; Kiyoshima K; Inokuchi J; Tatsugami K; Shiga KI; Koga H; Yamaguchi A; Naito S; Eto M BJU Int; 2016 Dec; 118(6):880-884. PubMed ID: 26991851 [TBL] [Abstract][Full Text] [Related]
9. [Biomarkers in metastatic castration-resistant prostate cancer]. Miller K Aktuelle Urol; 2015 Jan; 46(1):66-70. PubMed ID: 25658233 [TBL] [Abstract][Full Text] [Related]
10. Switch from abiraterone plus prednisone to abiraterone plus dexamethasone at asymptomatic PSA progression in patients with metastatic castration-resistant prostate cancer. Fenioux C; Louvet C; Charton E; Rozet F; Ropert S; Prapotnich D; Barret E; Sanchez-Salas R; Mombet A; Cathala N; Joulia ML; Molitor JL; Henriques J; Bonnetain F; Cathelineau X; Bennamoun M BJU Int; 2019 Feb; 123(2):300-306. PubMed ID: 30099821 [TBL] [Abstract][Full Text] [Related]
11. [Choice of new drugs in castration-resistant prostate cancer: predictive factors and effectiveness assessment]. Basset V; Flamand V; Crouzet S; Ploussard G Prog Urol; 2013 Oct; 23 Suppl 1():S44-8. PubMed ID: 24314738 [TBL] [Abstract][Full Text] [Related]
12. [Castration resistant prostate cancer 2015]. Merseburger AS; Böker A; Kuczyk MA; von Klot CA Aktuelle Urol; 2015 Jan; 46(1):59-65. PubMed ID: 25658232 [TBL] [Abstract][Full Text] [Related]
13. Association of early PSA decline and time to PSA progression in abiraterone acetate-treated metastatic castration-resistant prostate cancer; a post-hoc analysis of Japanese phase 2 trials. Nakayama M; Kobayashi H; Takahara T; Oyama R; Imanaka K; Yoshizawa K BMC Urol; 2016 Jun; 16(1):27. PubMed ID: 27278777 [TBL] [Abstract][Full Text] [Related]
14. Phase III, randomized, double-blind, multicenter trial comparing orteronel (TAK-700) plus prednisone with placebo plus prednisone in patients with metastatic castration-resistant prostate cancer that has progressed during or after docetaxel-based therapy: ELM-PC 5. Fizazi K; Jones R; Oudard S; Efstathiou E; Saad F; de Wit R; De Bono J; Cruz FM; Fountzilas G; Ulys A; Carcano F; Agarwal N; Agus D; Bellmunt J; Petrylak DP; Lee SY; Webb IJ; Tejura B; Borgstein N; Dreicer R J Clin Oncol; 2015 Mar; 33(7):723-31. PubMed ID: 25624429 [TBL] [Abstract][Full Text] [Related]
15. The Phase 3 COU-AA-302 Study of Abiraterone Acetate Plus Prednisone in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Stratified Analysis Based on Pain, Prostate-specific Antigen, and Gleason Score. Miller K; Carles J; Gschwend JE; Van Poppel H; Diels J; Brookman-May SD Eur Urol; 2018 Jul; 74(1):17-23. PubMed ID: 28939004 [TBL] [Abstract][Full Text] [Related]
16. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial. Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ; Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048 [TBL] [Abstract][Full Text] [Related]
17. Reversal of PSA progression on abiraterone acetate through the administration with food in men with metastatic castration-resistant prostate cancer. Stover JT; Moore RA; Davis K; Harrison MR; Armstrong AJ Prostate Cancer Prostatic Dis; 2015 Jun; 18(2):161-6. PubMed ID: 25777155 [TBL] [Abstract][Full Text] [Related]